Article
A rare EGFR mutation L747P conferred therapeutic efficacy to both gefitinib and osimertinib: A case report.
Lung cancer (Amsterdam, Netherlands) - 1 Dec 2020
Huang Xiaojie, Yang Yan, Wang Pingli, Wang Jia, Chen Songan, Mao Xinru, Ding Liren
Abstract excerpt
EGFR mutations, primarily sensitizing mutations such as exon 19 deletion and exon 21 point mutations, have been proven to act as predictive biomarkers for the response to tyrosine kinase inhibitors (TKIs). How patients harboring EGFR L747 P (a rare mutation located in exon 19) respond to EGFR-TKI is controversial. Some studies have described EGFR L747 P as providing intrinsic resistance to EGFR-TKIs, but others...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.